Cadenza Bio Raises $2.44M Series Seed Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Stay updated with breaking news from John Katzenellenbogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Less than 20% of diagnosed breast cancers are designated "triple-negative," lacking three types of receptors often found in other breast cancer types.
Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A high-fat diet further exacerbates the disease, which can progress to cirrhosis and liver failure.
URBANA, Ill. – Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A
Markets Leerink Partners analyst Geoff Porges maintained a Hold rating on Radius Health (RDUS – Research Report) on April 22. The company’s shares closed last Friday at $20.90. According to TipRanks.com, Porges is a 3-star analyst with an average return of 5.9% and a 49.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma. Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $29.00. Radius Health’s market cap is currently $980.1M and has a P/E ratio ...